International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Cyltezo®, First and Only FDA-approved Interchangeable Biosimilar to Humira®, Now Commercially Available in the United States

Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases. Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Boehringer Ingelheim A Value Through Innovation

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

Elevate Your Psoriasis Care and Boost Your Expertise: Join the IPC Psoriasis Masterclass for North America in Chicago

Getting to Know IPC’s Board Member André Carvalho: What Inspired Me to Specialize in Psoriasis

Beyond Skin-Deep: Tackling Gaps in Psoriasis Care

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.